Experience

Davis Polk is advising JP Morgan as financial adviser to Stryker Corporation in connection with its $2.775 billion acquisition of Sage Products, LLC from Madison Dearborn Partners. The…

Davis Polk is advising Biotie Therapies Corp. in connection with its combination agreement with Acorda Therapeutics, Inc. where Acorda will make a public tender offer in Finland and the…

Davis Polk is advising Affymetrix, Inc. in connection with its sale to Thermo Fisher Scientific Inc. for a total equity value of approximately $1.3 billion. The transaction, which is…

Davis Polk is advising Charles River Laboratories International, Inc. on its acquisition of WIL Research for approximately $585 million. The transaction, which is expected to close early in…

Davis Polk is advising China Cinda Asset Management Co., Ltd. (“China Cinda”) in connection with a proposed strategic investment by Sino Biopharmaceutical Limited. Pursuant to terms of the…

Davis Polk is advising Lazard Asia (Hong Kong) Limited as financial adviser to the special committee of the board of directors of Mindray Medical International Limited in connection with…

Davis Polk is advising Fujian Thai Hot Investment Co., Ltd in connection with its purchase of approximately 51.5% of the common stock of Alliance HealthCare Services, Inc. Fujian Thai Hot…

Davis Polk is advising Bio-Reference Laboratories, Inc. in connection with its approximately $1.47 billion acquisition by OPKO Health, Inc. Under the terms of the agreement, holders of Bio…

Davis Polk is advising Warner Chilcott plc in connection with its approximately $8.5 billion acquisition by Actavis, Inc. in a stock-for-stock transaction. The transaction is expected to…